BioCorRx Appoints Former White House Drug Policy Director to Advisory Board

BioCorRx Inc. (OTC: BICX), a developer of innovative treatment support programs for substance use disorders, has appointed Richard J. Baum to its Strategic Advisory Board. Baum brings nearly three decades of national drug policy experience, including serving as Acting Director of the White House Office of National Drug Control Policy (ONDCP) and Executive Director of the President’s Commission on Combating Drug Addiction and the Opioid Crisis. His career spans six presidential administrations, where he helped shape federal responses to evolving drug threats, including the opioid crisis. CEO Lourdes Felix welcomed Baum, stating his expertise will be invaluable as BioCorRx expands awareness of evidence-based addiction treatment and positions its programs within the broader continuum of care.

Baum will advise as BioCorRx advances its treatment and pharmaceutical strategies, including LUCEMYRA® (lofexidine), an FDA-approved non-opioid medication for mitigating opioid withdrawal symptoms, and BICX104, an investigational biodegradable naltrexone implant. Baum expressed particular interest in BICX104’s potential for methamphetamine use disorder, especially amid rising polysubstance use involving illicit fentanyl and methamphetamine. BioCorRx’s subsidiary, BioCorRx Pharmaceuticals Inc., focuses on commercializing LUCEMYRA and developing BICX104. The company also offers the UnCraveRx® Weight Loss Program, a medication-assisted program with concierge wellness specialists. For more information, visit www.BioCorRx.com.

Baum’s appointment comes at a critical time, as the U.S. continues to face significant challenges related to opioid use, addiction treatment, and recovery. According to the 2025 National Survey on Drug Use and Health, approximately 4.0 million people aged 12 or older had opioid use disorder in the past year, and about 2.7 million reported using methamphetamine. BioCorRx’s ongoing NIDA-supported clinical study of BICX104, alone and with bupropion, aims to address methamphetamine use disorder, a condition with no approved treatments. Baum’s policy expertise will help the company navigate regulatory and public health landscapes, potentially accelerating access to novel therapies. His advisory role underscores BioCorRx’s commitment to integrating evidence-based approaches into the treatment continuum, offering hope for improved outcomes in the fight against addiction.